Targeted BET inhibition with OPN-51107 synergizes with venetoclax in chronic lymphocytic leukemia

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Chronic lymphocytic leukemia (CLL) is an incurable blood cancer.
• Therapeutic resistance is a major challenge in CLL treatment.
• Bromodomain and extra-terminal proteins, like BRD4, are key regulators of gene expression in CLL and represent potential therapeutic targets.

Purpose of the Study:

• To investigate the anti-tumor activity of the BRD4 inhibitor OPN-51107, alone and in combination with the BCL-2 inhibitor venetoclax.
• To evaluate the efficacy of this combination in various CLL models, including therapy-resistant and high-risk patient samples.

Main Methods:

• Testing OPN-51107 and venetoclax in CLL cell lines and patient-derived CLL samples.
• Assessing the cytotoxic effects of single-agent and combination treatments.
• Analyzing efficacy in relapsed/refractory (R/R) samples and those with high-risk genetic features (e.g., ATM/TP53 deletions).

Main Results:

• OPN-51107 demonstrated anti-tumor activity as a single agent in CLL cell lines and patient samples.
• The combination of OPN-51107 and venetoclax showed synergistic cytotoxicity.
• This synergistic effect was observed in ibrutinib-resistant CLL cells and patient samples, irrespective of R/R status or genetic deletions.

Conclusions:

• The combination of OPN-51107 and venetoclax exhibits preclinical efficacy against therapy-resistant and high-risk CLL.
• This combination strategy warrants further clinical development for challenging CLL cases.
• Targeting BRD4 in combination with BCL-2 inhibition offers a potential new therapeutic avenue for CLL.